Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IPdR with Capecitabine and Radiotherapy in Rectal Cancer
NCT04406857Phase 1Terminated
- Sponsor
- National Cancer Institute
- Start
- Mar 2021
- Primary completion
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ropidoxuridine in rectal cancer, sponsored by National Cancer Institute. Primary endpoints: Maximum-tolerated Dose up to 38 days and Incidence of Dose-limiting Toxicities up to 38 days. Started Mar 2021; status: terminated.
02
Drugs
ropidoxuridine
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT04406857.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04406857.